Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Overall survival (OS) and stem cell transplant (SCT) in patients with FLT3 mutations treated with CPX-351 versus 7+3: Subgroup analysis of a phase III study of older adults with newly diagnosed, high-risk acute myeloid leukemia (AML). Medeiros, B. C., Hogge, D., Newell, L. F., Bixby, D. L., Solomon, S. R., Strickland, S., Lin, T. L., Erba, H., Powell, B. L., Podoltsev, N., Ryan, R., Chiarella, M., Louie, A., Lancet, J. E. AMER SOC CLINICAL ONCOLOGY. 2017
View details for DOI 10.1200/JCO.2017.35.15_suppl.e18507
View details for Web of Science ID 000411931708112